ASH 2018
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018
December 5, 2018Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …
Roche’s first-line Tecentriq combo scores accelerated FDA review
December 5, 2018Research and Development ASH 2018, Cancer, Roche, lung cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide …
Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018
December 5, 2018Research and Development ASH 2018, Janssen, darzalex, multiple myeloma, pharma
Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 …
Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018
December 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia
Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …
Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients
December 4, 2018Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma
In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …
AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
